Clinical Trials on Tooth Loss in Spain

Total 466 results

Sesen Bio, Inc.

Terminated

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Neoplasms, Squamous Cell | Mouth Neoplasms | Carcinoma, Squamous Cell of Head and Neck

Spain, Germany, Israel, Italy, Poland, United Kingdom, India, Argentina, France, Hungary, Serbia, Croatia, Ukraine, Brazil, Russian Federation, Mexico, Romania, Slovakia
Sol-Gel Technologies, Ltd.

Terminated

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Basal Cell Nevus Syndrome

United States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
Sylentis, S.A.

Completed

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Dry Eye Disease | Sjögren Syndrome

United States, Spain
Novartis Pharmaceuticals

Active, not recruiting

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)

Sjogren Syndrome

United States, Turkey, Belgium, Austria, Spain, France, Germany, Korea, Republic of, Guatemala, Portugal, China, Singapore, Brazil, Czechia, Chile, Poland, Mexico, Lithuania
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, France, Israel, Netherlands, Poland, Puerto Rico, Spain, Sweden
Hoffmann-La Roche

Completed

A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Basal Cell Carcinoma

United States, Spain, France, Germany, Netherlands, Russian Federation, Italy, Mexico, Austria, Canada
Novartis Pharmaceuticals

Recruiting

A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (NEPTUNUS-Ext)

Sjogrens Syndrome

United States, Spain, Austria, Belgium, Japan, Germany, Turkey, Hungary, Israel, Taiwan, Italy, France, Colombia, Argentina, Portugal, Sweden, Australia, Slovakia, United Kingdom, Guatemala, Brazil, Czechia, Poland, Bulgaria, Canada, Lith... and more
PellePharm, Inc.

Completed

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Basal Cell Nevus Syndrome

United States, Spain, Germany, United Kingdom, Italy, France, Belgium, Canada, Denmark, Netherlands
Bristol-Myers Squibb

Completed

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Autoimmune Disorder | Primary Sjögren's Syndrome

United States, Argentina, Belgium, France, Germany, Mexico, Poland, Spain, Netherlands, United Kingdom
Novartis Pharmaceuticals

Recruiting

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-2)

Sjogren Syndrome

Spain, Hungary, Germany, Canada, Greece, United Kingdom, Bulgaria, Japan, Colombia, United States, South Africa, Australia, China, Mexico, Israel, Lebanon, Taiwan, Argentina, Italy, France, Chile, Romania, India, Brazil, Poland, Slovakia, S...
Pfizer's Upjohn has merged with Mylan to form Viatris...

Terminated

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) (CHIP)

Adenomatous Polyposis Coli

Italy, United States, Belgium, Spain, Puerto Rico, Sweden, Israel, Czechia, Hong Kong, Hungary, Slovakia, South Africa, Ukraine, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (POETYK SjS-1)

Sjögren's Syndrome

United States, Australia, Germany, Korea, Republic of, China, Austria, Spain, Japan, Taiwan, Puerto Rico, Poland, Canada, Hungary, Chile, Denmark, France, Italy, Mexico, Peru, Netherlands, Belgium, Colombia, United Kingdom, Portugal, Sw... and more
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
University of Siena

Recruiting

AutoInflammatory Disease Alliance Registry (AIDA) (AIDA)

Behcet Syndrome | Uveitis | Hereditary Autoinflammatory Diseases | Schnitzler Syndrome | Scleritis | PFAPA Syndrome | Still Disease | Autoinflammatory Syndrome, Unspecified | Vexas Syndrome

Egypt, Spain, Turkey, Italy, Saudi Arabia, Greece, Belgium, United States, Algeria, Brazil, Germany, Ghana, Iran, Islamic Republic of, Lebanon, Morocco, Poland, Portugal, Romania, Taiwan
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions

Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland

Clinical Trials on Tooth Loss in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations